Predicting cognitive decline with amyloid-PET, plasma p-tau217, Aβ42/40, and p-tau217/Aβ42 in a community-based cohort - relevance for clinical trial enrollment.

ABSTRACT:

Introduction

Identifying at-risk individuals and selecting sensitive cognitive outcome measures are critical for designing efficient clinical trials targeting early Alzheimer's disease (AD) stages.

Methods

We compared amyloid beta (Aβ)-positron emission tomography (PET), plasma tau phosphorylated at threonine 217 (p-tau217), Aβ42/40, and p-tau217/Aβ42-related decline across neuropsychological and functional measures in 225 individuals (176 cognitively unimpaired (CU), 49 with mild cognitive impairment (MCI). Johnson-Neyman analysis identified the biomarkers, which were used as trial inclusion criteria to estimate sample sizes needed to detect a 30% slowing across cognitive outcomes.

Results

In the CU, using combined plasma Aβ42/40 and p-tau217 cut-offs for eligibility

SUBMITTER: Bachmann D 

PROVIDER: S-EPMC12538628 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature